Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Key Inclusion Criteria:

• Documented clinical diagnosis of idiopathic PD

• Able to administer study drug or have a caregiver throughout the duration of thestudy to help administer drug

• Willing to continue diet, exercise and medications reported at baseline consistentlythroughout participation in the trial. Essential changes are permitted

• If taking PD medications or any nutraceuticals, must be on a stable dose for atleast 30 days prior to Screening Visit. Essential changes will be permitted.

• If subject is taking chronic antidepressant or an anxiolytic, must be on a stabledose for at least 90 days prior to Screening. Essential changes will be permitted.

Key Exclusion Criteria:

• Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus

• Glycated hemoglobin (HbA1c) level ≥ 6.5%

• History of symptomatic hypoglycemia and/or documented plasma glucose levels of ≤ 50mg/dL with symptoms of hypoglycemia.

• Mini-Mental State Exam (MMSE) score of ≤ 24 at Screening

• Positive COVID-19 test at Screening and/or within 30 days of Screening

• Change in or escalation of dose of a chronic therapeutic agent that has thepotential to impair cognitive functioning per investigator within the last 8 weeksof Screening or during the study conduct.

• Chronic inflammation of nasal cavity, history of recurrent epistaxis, and/orclinically significant medical history of uncontrolled allergic rhinitis,rhino-conjunctivitis, or house dust mite allergy at Screening that may preventabsorption of study treatments.

• Insufficiently controlled respiratory disease (i.e., asthma, COPD).

• History of any significant neurologic or psychiatric disease other than PD

• Current diagnosis of epilepsy and had a history of seizures as an adult within 1year of Screening, or unexplained recent loss of consciousness, or history ofsignificant head trauma with loss of consciousness

• History of non-lacunar ischemic and/or hemorrhagic stroke with residual neurologicdeficits.

• Unstable or uncontrolled cardiac disease that could expose the subject to additionalsafety risks

• Use of the following medications: Insulin or any other anti-hyperglycemic agent(s)except if used during isolated gestational diabetes, Supplementation with GSH or anymedication shown to increase glutathione